Nevertheless, eight of 42 (19%) evaluable patients responded to nivolumab (tumor reduction beyond 30%), including two with complete responses, reported lead study author Anthony B. El-Khoueiry, MD, from the University of Southern California Norris Comprehensive Cancer Center in Los Angeles.
All the study patients had histologically confirmed advanced hepatocellular carcinoma (HCC) and a Child–Pugh score of B7 or below.
请不要误导,30万不是问题的话,pd1是救命最后一博 |